An observational study in Upper Gastrointestinal Cancer, Upper Gastrointestinal Precancerous Lesions and Upper Gastrointestinal Precancerous Conditions, sponsored by Changhai Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-12.
Sponsored by Changhai Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 110 studies in Gastrointestinal Neoplasms with a site in China — 44 open to participants now, 51 under way, 6 of them phase 3. Gastrointestinal Neoplasms · China.
Among the 110 studies in Gastrointestinal Neoplasms with a site in China, this one is the 9th largest by planned enrollment of the 22 observational ones that give a count, is one of 11 that started in 2026, is one of 22 observational ones, reaches primary completion later than 49 of the 50 other live ones, and was the 101st registered.
698 studies on the registry are indexed under Gastrointestinal Neoplasms; 211 are open to participants now.
Browse Gastrointestinal Neoplasms studies →44 of the 110 studies in Gastrointestinal Neoplasms with a site in China are open now. Recruiting first, the newest first:
Xijing Hospital · Sites in China
Ages 45–74 · Healthy volunteers
Hunan Cancer Hospital · Sites in China
Ages 45–74 · Healthy volunteers
Peking University Cancer Hospital & Institute · Sites in China
Ages 18+
Beijing GoBroad Hospital · Sites in China
Ages 18–70
DualityBio Inc. · Sites in China, United States, Australia
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 160 Gastrointestinal Neoplasms studies recruiting now, 121 (76%) set no upper age limit and 19 (12%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
110 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 26 · Phase 3 12 · Phase 4 4
First in 2005; this study’s year is marked. 11 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 200 across 168 observational studies indexed under Gastrointestinal Neoplasms.
Median enrollment 120 across the 88 interventional studies, 500 across the 22 observational. Of the 29 that completed or were terminated, 6 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 110 have an industry lead sponsor. The 10 most frequent:
Changhai Hospital is the lead sponsor of 355 studies on the registry; 136 are open to participants now.
Changhai Hospital has 1 study filed under Gastrointestinal Neoplasms — fewer than ten, so there is no comparison to draw.
16 of the studies in Gastrointestinal Neoplasms with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03303495Phase 3Sun Yat-sen UniversityA Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC | 2026-12-31 |
| NCT06966232Phase 3Sun Yat-sen UniversityProphylactic or Preemptive Entecavir in Patients With Gastrointestinal Cancer Who Are Inactive Hepatitis B Carriers | 2027-05-15 |
| NCT05252078Jiangxi Provincial Cancer HospitalAnlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients | 2026-11 |
| NCT05321316Peking University Cancer Hospital & InstituteNectin-4 Specific LMW PET Probe Imaging in Multiple Solid Tumors | 2026-12 |
| NCT06881043The First Hospital of Jilin UniversityThe Safety and Efficacy of Robotic Assisted Surgery Using Vessel Sealer Extend in Locally Advanced Gastric Cancer | 2026-12-01 |
Add all 16 to your calendar (.ics) → With an account.
Among the 110 studies in Gastrointestinal Neoplasms with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study is designed to collect magnetically-controlled capsule endoscopy (MCE) images, esophagogastroduodenoscopy (EGD) images, CT images, and histopathology results to establish a database for early upper gastrointestinal cancer, precancerous lesions, and precancerous conditions.
Images of MCE for UGIC are scarce, limiting the development of corresponding AI diagnostic model. We aim to create an image database with MCE images, EGD images, CT images, and histopathology results, in patients treated by ESD for early upper gastrointestinal cancer, or biopsy for precancerous lesions, and precancerous conditions, so as to facilitate image-based deep learning studies.
Tertiary Hospital
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Magnetically-controlled capsule endoscopy (MCE) images, esophagogastroduodenoscopy (EGD) images, and CT images for early upper gastrointestinal cancer, precancerous lesions, and precancerous conditions
ESD or biopsy for histopathology results
Magnetically-controlled capsule endoscopy (MCE) images, esophagogastroduodenoscopy (EGD) images, and CT images
Time frame: Prior to ESD or biopsy
Histopathology results
Time frame: During ESD or biopsy
Plan to share: Undecided
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Dec 2030, 57 months after the start.
Of 79 non-industry observational studies under Gastrointestinal Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 14. This study's planned 57 months is above that.
Counting every sponsor, half of 88 studies reached it within 43 months; a quarter within 16 and three quarters within 102.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.